AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19462434 — intervention group
Group type: COMPARATOR
Intervention: Control (no organic bowel disease)
Number of subjects: 199
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bowel disease
Number of subjects: 199
Study 19462434 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic bowel disease
Number of subjects: 199
Study 17578061 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary quality-of-life (QOL) intervention consisting of eight 90-min sessions addressing cognitive, physical, emotional, spiritual, and social functioning.
Number of subjects: 33
Study 17578061 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group).
Number of subjects: 33
Study 16624765 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% intralipid (500 ml once a day) from postburn day 4 for 10 consecutive days
Number of subjects: 67
Study 16624765 — intervention group
Group type: COMPARATOR
Intervention: Non-intralipid treatment (control group)
Number of subjects: 67
Study 15025657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric oxalate (Sensodyne Sealant)
Number of subjects: 13
Study 15025657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11020409 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction with posterior chamber intraocular lens implantation
Number of subjects: 400
Study 11020409 — intervention group
Group type: COMPARATOR
Intervention: Each year of increased age
Number of subjects: 400
Study 8806996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru‐Close drainage system
Number of subjects: 40
Study 8806996 — intervention group
Group type: COMPARATOR
Intervention: Hemovac drainage system
Number of subjects: 40
Study 2005162 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (n=21)
Number of subjects: 101
Study 2005162 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control group, n=22)
Number of subjects: 101
Study 6407293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of sustained-release nitroglycerin (SRNG)
Number of subjects: 10
Study 6407293 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg of sustained-release nitroglycerin (SRNG)
Number of subjects: 10
Study 6407293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30520243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide monotherapy
Number of subjects: 110
Study 28813878 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) with wrist robot-assisted therapy
Number of subjects: 24
Study 28813878 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with wrist robot-assisted therapy
Number of subjects: 24
Study 26101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 24
Study 26101175 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 24
Study 26101175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24339309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg followed by 0.1 μg/kg/h until the end of surgery
Number of subjects: 40
Study 24339309 — intervention group
Group type: COMPARATOR
Intervention: Saline (volume‐matched normal saline)
Number of subjects: 40
Study 24339309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 24339309 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 23023475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 155
Study 23023475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 19173690 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg HES 130/0.42
Number of subjects: 50
Study 19173690 — intervention group
Group type: COMPARATOR
Intervention: 10 ml/kg gelatin
Number of subjects: 50
Study 17502431 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon (30, 50, and 80 mg)
Number of subjects: 21
Study 17502431 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 21
Study 17502431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15143450 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5-7 mg/kg body weight)
Number of subjects: 60
Study 15143450 — intervention group
Group type: COMPARATOR
Intervention: nCPAP ventilation
Number of subjects: 60
Study 11435967 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg i.v. on days 0 and 4)
Number of subjects: 380
Study 11435967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 9740480 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 40 mg twice daily
Number of subjects: 116
Study 9740480 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg twice daily
Number of subjects: 116
Study 9740480 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg twice daily
Number of subjects: 116
Study 9740480 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 5/10 mg once daily
Number of subjects: 116
Study 9740480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 8047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 276
Study 8047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (weekend therapy)
Number of subjects: 276
Study 8047822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 8047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily (Italian study)
Number of subjects: 276
Study 8047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (weekend therapy, Italian study)
Number of subjects: 276
Study 2854116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 12
Study 2854116 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 12
Study 2854116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30901302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus R‐CHOP
Number of subjects: 838
Study 30901302 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus R‐CHOP
Number of subjects: 838
Study 28656129 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin + clarithromycin + omeprazole)
Number of subjects: 69
Study 28656129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus Bifidobacterium lactis B94 (5 × 10^9 CFU/dose) plus inulin (900 mg) for 14 days
Number of subjects: 69
Study 28656129 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 69
Study 28656129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus Bifidobacterium lactis B94 plus inulin
Number of subjects: 69
Study 26076572 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration (7ml of local anesthetic: 4 ml of 0.25% bupivacaine and 3 ml of 2% lidocaine)
Number of subjects: 134
Study 26076572 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 134
Study 26076572 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration
Number of subjects: 134
Study 23536132 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit-based education (ABE)
Number of subjects: 93
Study 23536132 — intervention group
Group type: COMPARATOR
Intervention: Guidelines and prompts
Number of subjects: 93
Study 23536132 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 93
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile and bonding with composite resin (G1)
Number of subjects: 70
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile, treatment with ascorbic acid and bonding with composite resin (G2)
Number of subjects: 70
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile, immersing in artificial saliva for 2 weeks and bonding with composite resin (G3)
Number of subjects: 70
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence and bonding with composite resin (G4)
Number of subjects: 70
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence, treatment with ascorbic acid and bonding with composite resin (G5)
Number of subjects: 70
Study 21426271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence, immersing in artificial saliva for 2 weeks and bonding with composite resin (G6)
Number of subjects: 70
Study 21426271 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-bleached specimens)
Number of subjects: 70
Study 19767078 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate at a dose of 20 U/kg
Number of subjects: 125
Study 19767078 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate at a dose of 10 U/kg
Number of subjects: 125
Study 19767078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16832632 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-acetate PET
Number of subjects: 32
Study 15001677 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET scanning in AD patients
Number of subjects: 122
Study 15001677 — intervention group
Group type: COMPARATOR
Intervention: (18)F‐FDG PET scanning in healthy elderly subjects (NC)
Number of subjects: 122
Study 15001677 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of coupled rCMRgl reductions between the EC and the ipsilateral T‐O cortex
Number of subjects: 122
Study 12584828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine 0.4 g/d by intramuscular injection for 3 months
Number of subjects: 44
Study 12584828 — intervention group
Group type: COMPARATOR
Intervention: Control group (liver protecting agents)
Number of subjects: 44
Study 12584828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine treatment
Number of subjects: 44
Study 10405773 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 22
Study 10405773 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 22
Study 8521190 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.1 IU/kg/day s.c.)
Number of subjects: 32
Study 8521190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 32
Study 2156644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus inhaled salbutamol (1 mg doses)
Number of subjects: 12
Study 2156644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus potassium, magnesium, or triamterene plus inhaled salbutamol (1 mg doses)
Number of subjects: 12
Study 2156644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus 50 mg of triamterene plus inhaled salbutamol (1 mg doses)
Number of subjects: 12
Study 2156644 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus inhaled salbutamol (1 mg doses)
Number of subjects: 12
Study 6249334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg
Number of subjects: 0
Study 6249334 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.3 mg
Number of subjects: 0
Study 30387037 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 446
Study 30387037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study 28682286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg, taken twice daily for 3 days)
Number of subjects: 20
Study 28682286 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal diclofenac (100 mg, placed once daily for 3 days)
Number of subjects: 20
Study 26145739 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of expanding transplants
Number of subjects: 0
Study 26145739 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic surgery with local tissues
Number of subjects: 0
Study 26145739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutural extension of the valve
Number of subjects: 0
Study 23756302 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolite isolation
Number of subjects: 29
Study 23756302 — intervention group
Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 29
Study 21554549 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil 100 mg
Number of subjects: 174
Study 21554549 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil 200 mg
Number of subjects: 174
Study 21554549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study 19135922 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced compression mammography (90 N)
Number of subjects: 0
Study 19135922 — intervention group
Group type: COMPARATOR
Intervention: Standard compression mammography (120 N)
Number of subjects: 0
Study 17509423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered empowerment intervention (EI)
Number of subjects: 90
Study 17509423 — intervention group
Group type: COMPARATOR
Intervention: Standardized HF patient education (Control)
Number of subjects: 90
Study 15521893 — intervention group
Group type: EXPERIMENTAL
Intervention: linezolid (600 mg)
Number of subjects: 12
Study 15521893 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide (300 mg)
Number of subjects: 12
Study 15521893 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 11465311 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 58
Study 11465311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9081124 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion technique (EXC)
Number of subjects: 100
Study 9081124 — intervention group
Group type: COMPARATOR
Intervention: Open endoaneurysmorrhaphy (OP)
Number of subjects: 100
Study 8442965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8442965 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium
Number of subjects: 40
Study 2878942 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 30
Study 2878942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (30 mg)
Number of subjects: 30
Study 2878942 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 30
Study 30817785 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sprint cycling (fatigue condition)
Number of subjects: 32
Study 30817785 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jump height
Number of subjects: 32
Study 28716796 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise (≤6 physiotherapy sessions)
Number of subjects: 704
Study 28716796 — intervention group
Group type: COMPARATOR
Intervention: Best practice advice (one physiotherapy session)
Number of subjects: 704
Study 28716796 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection then progressive exercise (≤6 sessions)
Number of subjects: 704
Study 28716796 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection then best practice advice (one session)
Number of subjects: 704
Study 26095263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 82
Study 26095263 — intervention group
Group type: COMPARATOR
Intervention: Anti-VEGF injections (control)
Number of subjects: 82
Study 24174588 — intervention group
Group type: COMPARATOR
Intervention: High third of total cerebral blood flow (CBF)
Number of subjects: 411
Study 24174588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low third of total cerebral blood flow (CBF)
Number of subjects: 411
Study 24174588 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle third of total cerebral blood flow (CBF)
Number of subjects: 411
Study 21340655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with energy target determined by repeated indirect calorimetry measurements (study group, n = 56)
Number of subjects: 130
Study 21340655 — intervention group
Group type: COMPARATOR
Intervention: 25 kcal/kg/day (control group, n = 56)
Number of subjects: 130
Study 21141017 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with triangular scleral flap (Group A, 11 eyes)
Number of subjects: 22
Study 21141017 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with rectangular scleral flap (Group B, 11 eyes)
Number of subjects: 22
Study 17199546 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in smokers (Group 3)
Number of subjects: 42
Study 17199546 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in non-smokers (Group 1)
Number of subjects: 42
Study 17199546 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP) in smokers (Group 4)
Number of subjects: 42
Study 17199546 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP) in non-smokers (Group 2)
Number of subjects: 42
Study 15180807 — intervention group
Group type: EXPERIMENTAL
Intervention: interictal ADC measurement
Number of subjects: 39
Study 11287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral protein load in type 2 DM patients without microalbuminuria (MA)
Number of subjects: 181
Study 11287757 — intervention group
Group type: COMPARATOR
Intervention: Acute oral protein load in healthy subjects
Number of subjects: 181
Study 11287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral protein load in type 2 DM patients with microalbuminuria (MA)
Number of subjects: 181
Study 9386023 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 60
Study 9386023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study 8485790 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and analgesia (lidocaine 2% with epinephrine 1:200,000, 20 ml over 30 min; morphine 0.10 mg.kg‐1 after catheter insertion and 0.05 to 0.10 mg.kg‐1 every 12 hr as needed)
Number of subjects: 20
Study 8485790 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone (nitrous oxide, oxygen, isoflurane, supplemented with intravenous fentanyl to a maximum of 10 micrograms.kg‐1)
Number of subjects: 20
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACNU and Futraful (FT)
Number of subjects: 3421
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (FT) only
Number of subjects: 3421
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACNU and FT
Number of subjects: 3421
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MMC and FT
Number of subjects: 3421
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ADM and FT
Number of subjects: 3421
Study 3101606 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 3421
Study 3101606 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3421
Study 2122024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reabilan HN (enteral nutrition)
Number of subjects: 19
Study 2122024 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 19
Study 1095794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 to 1,600 mg daily)
Number of subjects: 885
Study 1095794 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3 to 6 gm daily)
Number of subjects: 885
Study 1095794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 885
Study 1095794 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 885
Study 31219558 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone, 300 μg daily for 24 weeks
Number of subjects: 90
Study 31219558 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch for 24 weeks
Number of subjects: 90
Study 27736154 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium/Oxygen (heliox)
Number of subjects: 445
Study 27736154 — intervention group
Group type: COMPARATOR
Intervention: Air/O2
Number of subjects: 445
Study 25263393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg/day for 7 days
Number of subjects: 10
Study 25263393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24124445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephytinised fonio porridge (FWFP; 75% fonio-25% wheat)
Number of subjects: 16
Study 24124445 — intervention group
Group type: COMPARATOR
Intervention: Non-dephytinised fonio porridge (FFP)
Number of subjects: 16
Study 19830425 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 808
Study 19830425 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs
Number of subjects: 808
Study 19464401 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 329
Study 19464401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 16518320 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and spectroscopy (MRS) combined with neuropsychological (NP) tests
Number of subjects: 31
Study 16518320 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (T1-weighted)
Number of subjects: 31
Study 16518320 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS
Number of subjects: 31
Study 16518320 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and NP tests
Number of subjects: 31
Study 15553595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1, 40 microg infused twice daily for 28 days (group A)
Number of subjects: 86
Study 15553595 — intervention group
Group type: COMPARATOR
Intervention: Lumbar sympathectomy (group B)
Number of subjects: 86
Study 10910024 — intervention group
Group type: EXPERIMENTAL
Intervention: BioLogic-DTPF System (hemodiabsorption and push-pull sorbent-based pheresis)
Number of subjects: 0